For research use only. Not for therapeutic Use.
TAS6417 (CAT: I019823) is a potent and selective oral inhibitor of the fibroblast growth factor receptor (FGFR) tyrosine kinases. By inhibiting FGFR signaling, TAS6417 blocks the activation of downstream signaling pathways involved in cell proliferation, survival, and angiogenesis. TAS6417 has shown promising efficacy in preclinical studies against various FGFR-driven solid tumors, including lung cancer, gastric cancer, and bladder cancer. It has demonstrated antitumor activity in both in vitro and in vivo models and is being investigated as a potential targeted therapy for FGFR-altered cancers. TAS6417 holds promise as a novel treatment option for patients with FGFR-driven malignancies.
| Catalog Number | I019823 |
| CAS Number | 1661854-97-2 |
| Molecular Formula | C₂₃H₂₀N₆O |
| Purity | ≥95% |
| Reference | [1]. Hasako S, et al. TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations. Mol Cancer Ther. 2018 Aug;17(8):1648-1658.<br>[2]. Hibiki Udagawa, et al. TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations. Mol Cancer Res. 2019 Nov;17(11):2233-2243. |
